RESEARCH on the use of
long-acting β2-agonists (LABA),
commonly used to treat asthma,
has revealed an association
between regulatory actions by the
US Food and Drug Administration
(FDA) and the incidence of their
prescription.
When the FDA issued safety alerts
for LABA in 2005, a significant
decrease by 13.55% and 7.42% was
observed in children and adults,
respectively.
Published in the Journal of Allergy
and Clinical Immunology in Dec, the
work came from reputable sources
including Harvard and the FDA.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.